Headlines about Galapagos NV (NASDAQ:GLPG) have trended somewhat positive this week, according to Accern Sentiment Analysis. The research group rates the sentiment of news coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Galapagos NV earned a news impact score of 0.14 on Accern’s scale. Accern also gave media coverage about the biotechnology company an impact score of 45.742996523103 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
Several equities research analysts recently commented on GLPG shares. Zacks Investment Research raised shares of Galapagos NV from a “hold” rating to a “buy” rating and set a $86.00 price target for the company in a report on Friday, July 14th. Janney Montgomery Scott raised shares of Galapagos NV from a “sell” rating to a “neutral” rating in a report on Friday, July 7th. They noted that the move was a valuation call. Nomura dropped their target price on shares of Galapagos NV from $108.00 to $121.00 and set a “buy” rating for the company in a report on Thursday, June 22nd. Cowen and Company reissued a “buy” rating on shares of Galapagos NV in a research report on Wednesday, June 21st. Finally, BidaskClub raised shares of Galapagos NV from a “sell” rating to a “hold” rating in a research report on Thursday, August 17th. Four research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $108.14.
Shares of Galapagos NV (NASDAQ:GLPG) opened at 100.98 on Wednesday. Galapagos NV has a 1-year low of $57.16 and a 1-year high of $104.12.
COPYRIGHT VIOLATION NOTICE: “Galapagos NV (NASDAQ:GLPG) Earning Somewhat Favorable Media Coverage, Analysis Shows” was originally published by BBNS and is owned by of BBNS. If you are accessing this piece of content on another publication, it was stolen and reposted in violation of US & international trademark and copyright laws. The original version of this piece of content can be viewed at https://baseballnewssource.com/markets/galapagos-nv-glpg-receives-media-sentiment-rating-of-0-14/1700726.html.
About Galapagos NV
Galapagos NV is a Belgium-based biotechnology company. The Company’s activities are divided into two operating divisions: Research and Development (R & D) and Services. The R & D division is engaged in the discovery and development of small molecules. The Services division, offers target-to-drug discovery products and services to pharmaceutical and biotechnology companies and to patient foundations, encompassing target discovery and validation, screening and drug discovery through to delivery of pre-clinical candidates.
Receive News & Ratings for Galapagos NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galapagos NV and related companies with our FREE daily email newsletter.